no, dolce, they saw the interim analysis of the surrogate endpoints and walked. The number crunching boneheads saw a 'no' come out of the trial (which should really have been called a phase IIb) given the early chance Teva had to walk) and they walked. This is a fact which is indisputable - except by the delusional.
MSB Price at posting:
$1.11 Sentiment: Sell Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)